Ascletis Pharma Inc
Research Ascletis Pharma Inc (2VJ) on Bullrun: market cap EUR 1.18B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2VJ
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.18B
- Financial periodFY2025
- RevenueCNY 2.03M
- Revenue growth58.1%
- Net income-CNY 359.88M
- Free cash flow-CNY 418.75M
- Gross margin26.0%
Valuation Snapshot
latest market cap is EUR 1.18B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 2.03M | -CNY 359.88M | -CNY 418.75M | 26.0% | -0.37 | CNY 1.44B | CNY 5.16M | CNY 1.93B |
| FY2024 | CNY 1.28M | -CNY 300.94M | -CNY 343.73M | 57.3% | -0.3 | CNY 865.73M | CNY 7.63M | CNY 1.97B |
| FY2023 | CNY 56.60M | -CNY 144.72M | -CNY 242.95M | 45.9% | -0.13 | CNY 330.12M | CNY 8.42M | CNY 2.34B |
| FY2022 | CNY 54.09M | -CNY 314.84M | -CNY 216.87M | -45.6% | -0.29 | CNY 403.77M | CNY 4.24M | CNY 2.54B |
| FY2021 | CNY 76.88M | -CNY 199.02M | -CNY 154.13M | 51.0% | -0.18 | CNY 2.50B | CNY 2.75M | CNY 2.73B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 1.18B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ascletis Pharma Inc's market cap?
Ascletis Pharma Inc's market capitalization is EUR 1.18B.
What does Ascletis Pharma Inc do?
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.